PSMA-targeted radioligand therapy in metastatic prostate cancer: Comprehensive analysis of recent evidence
Open Access
- 27 December 2024
- journal article
- editorial
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 52 (4) , 1242-1245
Abstract
No abstract availableThis publication has 2 references indexed in Scilit:
- [225Ac]Ac‐PSMA for the treatment of metastatic castration‐resistant prostate cancer: A systematic review and meta‐analysisEuropean Journal of Clinical Investigation, 2024
- A Meta-Analysis and Meta-Regression of the Efficacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225 in Metastatic Prostate CancerEuropean Urology, 2024